Literature DB >> 24477941

Formation of activity cliffs is accompanied by systematic increases in ligand efficiency from lowly to highly potent compounds.

Antonio de la Vega de León1, Jürgen Bajorath.   

Abstract

Activity cliffs (ACs) are defined as pairs of structurally similar compounds sharing the same biological activity but having a large difference in potency. Therefore, ACs are often studied to rationalize structure-activity relationships (SARs) and aid in lead optimization. Hence, the AC concept plays an important role in compound development. For compound optimization, ligand efficiency (LE) represents another key concept. LE accounts for the relation between compound potency and mass. A major goal of lead optimization is to increase potency and also LE. Despite their high relevance for drug development, the AC and LE concepts have thus far not been considered in combination. It is currently unknown how compounds forming ACs might be related in terms of LE. To explore this question, ACs were systematically identified on the basis of high-confidence activity data and LE values for cliff partners were determined. Surprisingly, a significant increase in LE was generally detected for highly potent cliff partners compared to their lowly potent counterparts, regardless of the compound classes and their targets. Hence, ACs reveal chemical modifications that determine SARs and improve LE. These findings further increase the attractiveness of AC information for compound optimization and development.

Mesh:

Substances:

Year:  2014        PMID: 24477941      PMCID: PMC3933589          DOI: 10.1208/s12248-014-9567-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

2.  Exploring activity cliffs in medicinal chemistry.

Authors:  Dagmar Stumpfe; Jürgen Bajorath
Journal:  J Med Chem       Date:  2012-01-27       Impact factor: 7.446

3.  MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs.

Authors:  Xiaoying Hu; Ye Hu; Martin Vogt; Dagmar Stumpfe; Jürgen Bajorath
Journal:  J Chem Inf Model       Date:  2012-04-17       Impact factor: 4.956

4.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.

Authors:  Emanuele Perola
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors.

Authors:  Daisuke Tanaka; Yusuke Tsuda; Takaaki Shiyama; Tamiki Nishimura; Naoki Chiyo; Yukio Tominaga; Nobuyuki Sawada; Tsutomu Mimoto; Naoto Kusunose
Journal:  J Med Chem       Date:  2010-12-30       Impact factor: 7.446

6.  On outliers and activity cliffs--why QSAR often disappoints.

Authors:  Gerald M Maggiora
Journal:  J Chem Inf Model       Date:  2006 Jul-Aug       Impact factor: 4.956

7.  The role of molecular size in ligand efficiency.

Authors:  Charles H Reynolds; Scott D Bembenek; Brett A Tounge
Journal:  Bioorg Med Chem Lett       Date:  2007-05-17       Impact factor: 2.823

8.  Recent progress in understanding activity cliffs and their utility in medicinal chemistry.

Authors:  Dagmar Stumpfe; Ye Hu; Dilyana Dimova; Jürgen Bajorath
Journal:  J Med Chem       Date:  2013-09-13       Impact factor: 7.446

9.  Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets.

Authors:  Jameed Hussain; Ceara Rea
Journal:  J Chem Inf Model       Date:  2010-03-22       Impact factor: 4.956

10.  Frequency of occurrence and potency range distribution of activity cliffs in bioactive compounds.

Authors:  Dagmar Stumpfe; Jürgen Bajorath
Journal:  J Chem Inf Model       Date:  2012-08-17       Impact factor: 4.956

View more
  1 in total

1.  Advancing the activity cliff concept, part II.

Authors:  Dagmar Stumpfe; Antonio de la Vega de León; Dilyana Dimova; Jürgen Bajorath
Journal:  F1000Res       Date:  2014-03-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.